市场调查报告书
商品编码
1159200
肌强直性营养不良治疗药的全球市场(2022年~2028年)Myotonic Dystrophy Drug Market 2022-2028 |
全球肌强直性营养不良治疗药的市场规模在预测期间内预计将以7.6%的年复合成长率增长。创新疾病治疗药的销售,研究开发的活跃,肌强直性营养不良的发病率上升,促进了市场的成长。
本报告提供全球肌强直性营养不良治疗药市场相关调查分析,提供市场概要,竞争情形,市场分析,企业简介等系统性资讯。
Global Myotonic dystrophy drug Market Size, Share & Trends Analysis Report by Drug Type (Sodium Channel Blockers, NSAIDs, Antidepressants, and Others), by Route of Administration (Oral, Intravenous), and by Distribution Channel( Online Pharmacies, Offline Pharmacies) Forecast 2022-2028
The global myotonic dystrophy drug market is anticipated to grow at a substantial CAGR of 7.6% during the forecast period. Myotonic dystrophy refers to a series of long-term hereditary illness that affects the body muscle. Muscle atrophy develops with time as a symptom. The global myotonic dystrophy drug market is growing due to the launch of innovative disease therapies and increased research and developments. Additionally, a rise in the incidence of myotonic dystrophy along with the demand for effective treatment with innovative drugs is estimated to boost the market growth. Wider coverage in the health insurance sector and incidences of chronic illnesses such as arthritis, neurovascular conditions will help the myotonic dystrophy market to grow in the forecast period.
The global myotonic dystrophy drug market is segmented based on the drug type, route of administration, and distribution channel. Based on the drug type, the market is segmented into anti-myotonic drugs , NSAIDs, antidepressants, and others.. Based on the route of administration, the market is sub-segmented into oral and intravenous. Based on the distribution channel, the market is sub-segmented into the online pharmacy and offline pharmacies.
Regionally, the global myotonic dystrophy drug market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to hold the major share and dominate the global myotonic dystrophy drug market in 2021. Increasing research & development activities, along with an increase in the number of clinical trials for muscular dystrophy drugs have boosted the regional market growth. The Asia-Pacific region is expected to be the fastest growing region. This is generally due to the various awareness programs from the Parental Drug Association and the trending use of effervescent tablets in recent decades. Various research and development of key market players in this region to treat different diseases by developing novel drugs are also helping the market to hold a prominent share in this region.
The major companies serving the global myotonic dystrophy drug market include ANI Pharmaceuticals, Inc., Lupin Ltd., Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd., and many more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, On May 3, 2021, ICREA Researcher Professor and head of the Biosensors for Bioengineering group at IBEC developed a three-dimensional model for myotonic dystrophy using bioengineering technique and patient cells.
Research Methodology
The market study of the global myotonic dystrophy drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: